Le Lézard12h
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir?the company's twice-yearly injectable HIV ...
Visteon Announces 2024 Financial Results and 2025 Outlook
Visteon Corporation (NASDAQ: VC) today reported fourth quarter and full-year 2024 financial results. Highlights include: ...
The Daily Campus16h
Connecticut responds to Trump administration actions
President Donald Trump has had one of the most active first months in office of any U.S. president. Since Trump’s inauguration, Connecticut Attorney General William Tong has been active in challenging ...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...